Fulgent Genetics Inc (FLGT) Stock Price, Quote & News

Company Profile

Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer serv...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 626 350 0537

Fax: 626 454 1667

Website: www.fulgentgenetics.com

Address:

4399 Santa Anita Avenue, El Monte, United States

Sexydream Oct. 22 at 5:01 PM

$FLGT all this hype and stock is back down to 10/1 price. 🤣

0 · Reply

jf152 Oct. 21 at 7:38 PM

$FLGT

0 · Reply

CrayP Oct. 21 at 5:17 PM

$FLGT https://x.com/3Things10/status/1971968264092762131

0 · Reply

jf152 Oct. 21 at 3:10 PM

$FLGT

0 · Reply

Sexydream Oct. 21 at 2:44 PM

$FLGT 18.56 gap created on 8/4 looking mighty fresh. Will get filled for sure. Only fools hold this long. Remember, ceo took this stock down from 189 to 24. He also shorted the stock privately. Criminal guy and u guys worshipping him. Fools!

2 · Reply

twitweetz Oct. 21 at 4:33 AM

$FLGT I love you Ming. Keep doing what you do. Faked me out that's for sure, but I guess you did say in or around June...

2 · Reply

Doozio Oct. 21 at 3:36 AM

unless it’s a MNDY 🐑 suck in? $FLGT aboutit it’s 🐒🍌🧠⏰♾️

0 · Reply

jf152 Oct. 20 at 4:12 PM

$FLGT Sexydream has hallucinations of imaginary walls and gaps. New 52 week high.

1 · Reply

james899 Oct. 17 at 8:40 AM

$FLGT Recently it was up 7% in pre market (was gone in trading session), now again up 4%. What does this activity hint at 🤔

0 · Reply

Sexydream Oct. 10 at 3:16 PM

$FLGT well well well...... Stock has hit the wall hard. Again lolll. Watch the crash landing back to the teens again

2 · Reply

Fulgent Shares Preliminary Data from Poster Presentation at ESMO 2025 Conference

Oct 16, 2025, 7:00 AM EDT - 9 days ago

Fulgent to Announce Third Quarter 2025 Financial Results on Friday, November 7, 2025

Sep 8, 2025, 1:58 PM EDT - 6 weeks ago

Fulgent Genetics: Core Growth Re-Acceleration And Gross Margin Expansion Are On Track (Reiterate Buy)

Aug 1, 2025, 12:28 PM EDT - 3 months ago

Fulgent Genetics, Inc. (FLGT) Q2 2025 Earnings Call Transcript

Aug 1, 2025, 7:00 AM EDT - 3 months ago

Fulgent Reports Second Quarter 2025 Financial Results

Jul 17, 2025, 7:00 AM EDT - 3 months ago

Fulgent Genetics Receives EU CE Mark for FulgentExome & FulgentPLM

Jul 10, 2025, 4:05 PM EDT - 3 months ago

Fulgent to Announce Second Quarter 2025 Financial Results on Friday, August 1, 2025

Jun 10, 2025, 10:00 AM EDT - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Fulgent Genetics, Inc. (FLGT) And Encourages Shareholders to Reach Out

Jun 9, 2025, 10:00 AM EDT - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulgent Genetics, Inc. (FLGT) and Encourages Shareholders to Learn More About the Investigation

Jun 8, 2025, 10:00 AM EDT - 4 months ago

Fulgent Genetics, Inc. (FLGT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Jun 6, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Fulgent Genetics, Inc. (FLGT) Shareholders to Inquire about Securities Investigation

Jun 5, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Fulgent Genetics, Inc. (FLGT) And Encourages Investors to Connect

Jun 4, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Fulgent Genetics, Inc. (FLGT) Stockholders to Inquire about Securities Investigation

Jun 3, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulgent Genetics, Inc. (FLGT) and Encourages Investors to Learn More About the Investigation

Jun 2, 2025, 10:00 AM EDT - 5 months ago

Fulgent Genetics, Inc. (FLGT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 30, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Fulgent Genetics, Inc. (FLGT) And Encourages Stockholders to Connect

May 29, 2025, 10:00 AM EDT - 5 months ago

Fulgent Genetics, Inc. (FLGT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

May 28, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulgent Genetics, Inc. (FLGT) and Encourages Stockholders to Learn More About the Investigation

May 27, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Fulgent Genetics, Inc. (FLGT) Investors to Inquire about Securities Investigation

May 24, 2025, 9:19 PM EDT - 5 months ago

FLGT Investors Have Opportunity to Join Fulgent Genetics, Inc. Fraud Investigation with the Schall Law Firm

May 19, 2025, 8:11 AM EDT - 5 months ago

Wolf Haldenstein Adler Freeman & Herz LLP is investigating Fulgent Genetics, Inc

May 2, 2025, 12:27 PM EDT - 6 months ago

Fulgent Genetics, Inc. (FLGT) Q1 2025 Earnings Call Transcript

May 2, 2025, 7:00 AM EDT - 6 months ago

Fulgent Reports First Quarter 2025 Financial Results

Apr 10, 2025, 4:05 PM EDT - 7 months ago

Fulgent to Announce First Quarter 2025 Financial Results on Friday, May 2, 2025

Apr 4, 2025, 2:30 PM EDT - 7 months ago

Stock Picks From Seeking Alpha's March 2025 New Analysts

AI ARGX CCL CEPU CF CROX CUK

Mar 20, 2025, 5:46 AM EDT - 7 months ago

Fulgent Genetics: Undervalued, CFO Buying, And Promising Drug Candidates Make It A Buy

Feb 28, 2025, 11:57 AM EST - 8 months ago

Fulgent Genetics, Inc. (FLGT) Q4 2024 Earnings Conference Call Transcript

Feb 28, 2025, 7:00 AM EST - 8 months ago

Fulgent Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 6, 2025, 4:05 PM EST - 9 months ago

Fulgent to Announce Fourth Quarter and Full Year 2024 Financial Results on Friday, February 28, 2025

Feb 4, 2025, 4:00 PM EST - 9 months ago

Foundation Medicine to Launch Hereditary Germline Tests, FoundationOne®Germline and FoundationOne®Germline More, in the United States Through a Partnership with Fulgent Genetics

Dec 24, 2024, 1:25 AM EST - 10 months ago

Fulgent Genetics: High Insider Ownership Supports Asymmetric Upside

Nov 11, 2024, 2:07 AM EST - 1 year ago

Fulgent Genetics, Inc. (FLGT) Q3 2024 Earnings Call Transcript

Nov 8, 2024, 7:00 AM EST - 1 year ago

Fulgent Reports Third Quarter 2024 Financial Results

Nov 5, 2024, 8:00 AM EST - 1 year ago

Fulgent to Participate in Upcoming Conferences

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Fulgent Genetics Awarded Contract by the U.S. Department of Veterans Affairs to Provide Hereditary Cancer, Pharmacogenetic and Other Genetic Testing to Veterans1

Oct 17, 2024, 4:05 PM EDT - 1 year ago

Fulgent to Announce Third Quarter 2024 Financial Results on Friday, November 8, 2024

Sep 25, 2024, 11:32 AM EDT - 1 year ago

Fulgent Genetics: An NCAV Pick With Profit And Growth Potential

Sep 9, 2024, 12:05 PM EDT - 1 year ago

Fulgent Genetics: Core Growth Re-Acceleration Will Be The Critical Catalyst

Aug 2, 2024, 10:24 AM EDT - 1 year ago

Fulgent Genetics, Inc. (FLGT) Q2 2024 Earnings Call Transcript

Aug 2, 2024, 7:00 AM EDT - 1 year ago

Fulgent Reports Second Quarter 2024 Financial Results

Jul 11, 2024, 4:05 PM EDT - 1 year ago

Fulgent to Announce Second Quarter 2024 Financial Results on Friday, August 2, 2024

Jun 10, 2024, 1:00 AM EDT - 1 year ago

Press release Biocartis NV: Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing

NEO

Jun 6, 2024, 11:36 AM EDT - 1 year ago

Fulgent Genetics: Growth Is Returning

Jun 3, 2024, 8:00 AM EDT - 1 year ago

Fulgent Data at ASCO 2024 Highlights Antitumor Activity from Lead Therapeutic Oncology Candidate, FID-007, in Head and Neck Cancer

May 24, 2024, 8:00 AM EDT - 1 year ago

Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2024 Annual Meeting

May 14, 2024, 4:05 PM EDT - 1 year ago

Moffitt Cancer Center and Fulgent Pharma Join Forces to Revolutionize Cancer Therapeutics

Sexydream Oct. 22 at 5:01 PM

$FLGT all this hype and stock is back down to 10/1 price. 🤣

0 · Reply

jf152 Oct. 21 at 7:38 PM

$FLGT

0 · Reply

CrayP Oct. 21 at 5:17 PM

$FLGT https://x.com/3Things10/status/1971968264092762131

0 · Reply

jf152 Oct. 21 at 3:10 PM

$FLGT

0 · Reply

Sexydream Oct. 21 at 2:44 PM

2 · Reply

twitweetz Oct. 21 at 4:33 AM

$FLGT I love you Ming. Keep doing what you do. Faked me out that's for sure, but I guess you did say in or around June...

2 · Reply

Doozio Oct. 21 at 3:36 AM

unless it’s a MNDY 🐑 suck in? $FLGT aboutit it’s 🐒🍌🧠⏰♾️

0 · Reply

jf152 Oct. 20 at 4:12 PM

$FLGT Sexydream has hallucinations of imaginary walls and gaps. New 52 week high.

1 · Reply

james899 Oct. 17 at 8:40 AM

$FLGT Recently it was up 7% in pre market (was gone in trading session), now again up 4%. What does this activity hint at 🤔

0 · Reply

Sexydream Oct. 10 at 3:16 PM

$FLGT well well well...... Stock has hit the wall hard. Again lolll. Watch the crash landing back to the teens again

2 · Reply

Doozio Oct. 7 at 4:55 PM

If so many names just busted out. $FLGT etaboutit. It’s 🐒🍌🧠⏰♾️ still spreading on the DLO

1 · Reply

jf152 Oct. 1 at 5:23 PM

$FLGT 52 week high. @Sexydream

1 · Reply

jf152 Sep. 30 at 8:34 PM

Strong volume starting at 3:48 pm. $FLGT

0 · Reply

jf152 Sep. 27 at 2:29 AM

I said : where is $17? $FLGT

0 · Reply

jf152 Sep. 24 at 8:39 PM

Silly troll. Must have lost his house trying to short $FLGT

0 · Reply

LelaTrowery449 Sep. 21 at 2:37 PM

$FLGT Healthcare technology niche. Testing support level. Volume decline concerning. Growth concerns.

0 · Reply

bdubs84 Sep. 19 at 4:41 PM

$FLGT this stock basically at the mercy of the HRSA audit and the ability to unlock all the cash in their balance sheet. With no decision confirmed or in sight, this stock basically goes nowhere.

1 · Reply

jf152 Sep. 18 at 10:48 PM

I am once again asking... WHERE IS $17? $FLGT

1 · Reply

Doozio Sep. 17 at 3:20 PM

Out of the tightness $FLGT etaboutit 🐒🍌🧠⏰♾️

0 · Reply

FloatWolf Sep. 15 at 9:18 AM

$FLGT Competitive space; differentiation and margin improvement matter

0 · Reply

Sexydream Sep. 12 at 5:14 PM

$FLGT with all the money I made shorting this stock, I was able to buy tsla bull leveraged etf, up 200% on it. Thanks fulgent for never stop being shitty! Paid off biggg

1 · Reply

wutzwrong Sep. 11 at 4:19 PM

$FLGT added

1 · Reply

Market Cap	722.98M
Revenue (ttm)	283.47M
Net Income (ttm)	-42.71M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-15.07%
Debt to Equity Ratio	0.00

Volume	129,300
Avg Vol	211,540
Day's Range	N/A - N/A
Shares Out	30.61M
Stochastic %K	62%
Beta	0.97
Analysts	Sell
Price Target	$25.33